Cargando…
Treatment of gastrointestinal stromal tumours in paediatric and young adult patients with sunitinib: a multicentre case series
BACKGROUND: Gastrointestinal stromal tumours (GIST) are rarely encountered mesenchymal tumours of the gastrointestinal tract (1.5 people per 100,000/year) that are even more rarely seen in paediatric patients (1–2% of all cases). The standard treatment for advanced adult GIST is imatinib with suniti...
Autores principales: | Rutkowski, Piotr, Magnan, Heather, Chou, Alexander J., Benson, Charlotte |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5674814/ https://www.ncbi.nlm.nih.gov/pubmed/29110655 http://dx.doi.org/10.1186/s12885-017-3727-1 |
Ejemplares similares
-
Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study
por: Gelderblom, Hans, et al.
Publicado: (2020) -
The Landmark Series: Systemic Therapy for Resectable Gastrointestinal Stromal Tumors
por: Keung, Emily Z., et al.
Publicado: (2020) -
Alternative schedules or integration strategies to maximise treatment duration with sunitinib in patients with gastrointestinal stromal tumours
por: SAPONARA, MARISTELLA, et al.
Publicado: (2014) -
The analysis of the long-term outcomes of sorafenib therapy in routine practice in imatinib and sunitinib resistant gastrointestinal stromal tumors (GIST)*
por: Rutkowski, Piotr, et al.
Publicado: (2017) -
Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives
por: Mulet-Margalef, Nuria, et al.
Publicado: (2016)